Story · Securities and Exchange Commission
Organon & Co. Shareholders Approve Merger with Sun Pharma USA
On July 23, 2026, Organon & Co. announced that its shareholders approved the proposed merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting. The merger agreement, dated April 26, 2026, involves Sun Pharma's merger subsidiary combining with Organon, with Organon surviving as a wholly owned subsidiary of Sun Pharma USA. Shareholders also passed a non-binding advisory vote on merger-related compensation for Organon's named executive officers. The meeting established a quorum with 74.5% of outstanding shares represented. Final certified voting results will be filed with the SEC in a Form 8-K. The deal marks a major step in Sun Pharma's acquisition of the U.S.-based pharmaceutical company.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection